Medical and Health Sciences | Article | Published 2019

Pharmacological Treatment Strategies In Metabolic Syndrome

Authors:
Collection: British Journal of Medical & Health Sciences (BJMHS)
Keywords: metabolic syndrome; abdominal obesity; insulin resistance; dyslipidemia; hypertension;

Abstract

Metabolic syndrome (MS) is considered the risk for the development of the cardiovascular disease (CVD) and type II diabetes mellitus (T2DM) and consisted of several components such as abdominal obesity, hypertension, dyslipidemia, impairment of the glucose tolerance and insulin resistance. This article summarizes the treatment strategies of the metabolic syndrome from the lifestyle modification to the medication therapy. Early detection and start of the interventions will allow reduction of the development of the T2DM and CVD.

References

  1. [1] Abete I., Goyenechea E., Zulet M., Martinez J. (2011). Obesity and metabolic syndrome: potential benefit from specific nutritional components. Nutr. Metab. Cardiovasc. Dis. 21, B1–B15. 10.1016/j.numecd.2011.05.001
  2. [2] Uzokov J. Optimization antihypertensive therapy in patients with metabolic syndrome //European journal of cardiovascular nursing. – 1 olivers yard, 55 city road, london ec1y 1sp, england : sage publications ltd, 2015. – т. 14. – с. S106-s107.
  3. [3] Ford E. S., Giles W. H., Dietz W. H. (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356–359. 10.1001/jama.287.3.356
  4. [4] Uzokov J. et al. Ps 14-47 Combined Antihypertensive Therapy With Angiotensin Ii Receptor Antagonist And Calcium Channel Blocker In Patients With Metabolic Syndrome //Journal of Hypertension. – 2016. – Т. 34. – С. e447.
  5. [5] Hawley S. A., Gadalla A. E., Olsen G. S., Hardie D. G. (2002). The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51, 2420–2425. 10.2337/diabetes.51.8.2420
  6. [6] Lutfullayevich A. A. et al. GW28-e0698 Telmisartan with amlodipine versus lisinopril with amlodipine on home blood pressure variability in patients with metabolic syndrome //Journal of the American College of Cardiology. – 2017. – Т. 70. – №. 16 Supplement. – С. C138.
  7. [7] Alyavi A., Alyavi B., Uzokov J. Efficiency and safety of rosuvastatin in patients with metabolic syndrome //Atherosclerosis. – 2017. – Т. 263. – С. e245.
  8. [8] Mukhamedova M. et al. P120 Relationship between left ventricular global function index and cardiac systolic functions in patients with chronic ischemic disease of the heart and diabetes mellitus //European Heart Journal-Cardiovascular Imaging. – 2019. – Т. 20. – №. Supplement_3. – С. jez147. 008.
  9. [9] Babaev M. et al. P2533 Influence of l-arginine aspartate on vascular markers in hypertensive patients with metabolic syndrome //European Heart Journal. – 2018. – Т. 39. – №. suppl_1. – С. ehy565. P2533.
  10. [10] Alyavi A., Alyavi B., Uzokov J. Low glycemic diet improves lipid profile in patients with coronary heart disease //Atherosclerosis. – 2018. – Т. 275.
  11. [11] Alyavi A., Alyavi B., Uzokov J. Efficiency and safety of rosuvastatin in patients with metabolic syndrome //Atherosclerosis. – 2017. – Т. 263. – С. e245.
  12. [12] Uzokov J., Alyavi A., Alyavi B. Influence of combination therapy of rosuvastatin and telmisartan on vascular and metabolic profile in hypercholesterolemic patients with metabolic syndrome //Atherosclerosis. – 2017. – Т. 263. – С. e241.
  13. [13] Kastorini C.-M., Milionis H. J., Esposito K., Giugliano D., Goudevenos J. A., Panagiotakos D. B. (2011). The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J. Am. Coll. Cardiol. 57, 1299–1313. 10.1016/j.jacc.2010.09.073
  14. [14] Marvasti T. B., Adeli K. (2010). Pharmacological management of metabolic syndrome and its lipid complications. DARU J. Pharm. Sci. 18:146.
  15. [15] Uzokov J. J., Alyavi A. Comparison of enalapril-amlodipine and captopril-indapamide combinations in the management of hypertension patients with metabolic syndrome: P392 //European Journal of Heart Failure. – 2015. – Т. 17.
  16. [16] Jamol U., Aniskhon A. GW27-e0518 Effects of telmisartan/amlodipine combination compared to single monotherapies in hypertensive patients with metabolic syndrome //Journal of the American College of Cardiology. – 2016. – Т. 68. – №. 16 Supplement. – С. C137.
  17. [17] Romeo G. R., Lee J., Shoelson S. E. (2012). Metabolic syndrome, insulin resistance, and roles of inflammation–mechanisms and therapeutic targets. Arterioscler. Thromb. Vasc. Biol. 32, 1771–1776. 10.1161/ATVBAHA.111.241869
  18. [18] Staessen J. A. et al. The Pulse of Asia 2016 Seoul, September 24-26, 2016, Seoul, Republic of Korea: Abstracts //Pulse. – 2016. – Т. 4. – №. 2-3. – С. 93-164.
  19. [19] Uzokov J. K. et al. Efficacy and safety of combined antihypertensive therapy with ramipril and moxonidine in patients with metabolic syndrome //Journal of the American Society of Hypertension. – 2016. – Т. 10. – №. 4. – С. e54.
  20. [20] Russell J. C., Proctor S. D. (2006). Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis. Cardiovasc. Pathol. 15, 318–330. 10.1016/j.carpath.2006.09.001
  21. [21] Lara-Castro C., Luo N., Wallace P., Klein R. L., Garvey W. T. (2006). Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55, 249–259. 10.2337/diabetes.55.01.06.db05-1105.
  22. [22] Hawley S. A., Gadalla A. E., Olsen G. S., Hardie D. G. (2002). The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51, 2420–2425. 10.2337/diabetes.51.8.2420.
  23. [23] Ahmedov I. et al. Features of hyperreninemic aldosteronism in hypertension patients with metabolic syndrome: 87 //European Journal of Preventive Cardiology. – 2016. – Т. 23. – №. 1.
  24. [24] Uzokov J. et al. Ps 14-54 Efficacy And Safety Of Combined Antihypertensive Therapy With Lisinopril And Moxonidine In Patients With Metabolic Syndrome //Journal of Hypertension. – 2016. – Т. 34. – С. e448-e449.
  25. [25] Gluckman P. D., Hanson M. A. (2004). The developmental origins of the metabolic syndrome. Trends Endocrinol. Metab. 15, 183–187. 10.1016/j.tem.2004.03.002.
  26. [26] Uzokov J. K., Alyavi B. A., Abdullaev A. X. Combined therapy with rosuvastatin and ezetimibe on inflammatory state and pro-inflammatory cytokines in patients with coronary heart disease and metabolic syndrome //European journal of heart failure. – 111 river st, hoboken 07030-5774, nj usa : wiley, 2019. – т. 21. – с. 133-133.
  27. [27] Cherian S., Kumar R. V., Augusti K., Kidwai J. (1992). Antidiabetic effect of a glycoside of pelargonidin isolated from the bark of Ficus bengalensis Linn. Indian J. Biochem. Biophys. 29, 380–382.
  28. [28] Barazzoni R., Cappellari G. G., Ragni M., Nisoli E. (2018). Insulin resistance in obesity: an overview of fundamental alterations. Eat. Weight Disord. 23. 149–157. 10.1007/s40519-018-0481-6.
Loading...
0

Views

0

Reads

0

Comments

0

Reviews

0

Liked

0

Shared

0

Bibliography

0

Citations

Like and share on

Cite this publication

Copy text below and use in your article